Monro, Inc. (Nasdaq: MNRO) says in its latest quarterly filing that a goodwill test, run because its share price had fallen, found the business worth more than its carrying value as of September 26, 2026. That carrying value works out to about $18.32 a share of book value. The stock closed at $11.63 on November 3. Kingdom Capital, a small-cap fund that has argued for months that Monro will be sold, reads the gap as a sign of credible bids. Monro's rights plan expires on November 6.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Price: $11.63 at the November 3, 2026 close, down 5.4% from $12.30 on October 29 and down 18.7% from $14.30 before the second-quarter report.
- Market value: about $364 million on 31,326,927 shares outstanding, by our math from the 10-Q share counts.
- Book value: shareholders' equity of $573.9 million at September 26, 2026, or about $18.32 a share, so the stock trades near 0.63 times book.
- Goodwill: $736.4 million, more than total equity. Tangible book value is negative, about -$169 million by our math.
- The test: Monro treated the sustained fall in its market value as a triggering event and found the fair value of its single reporting unit exceeded its carrying value, including goodwill. It recorded no impairment.
- Calendar: Icahn Enterprises owns about 16.9%. The 17.5% rights plan expires November 6, 2026, per the 10-Q.
- Dividend: $0.28 a quarter, or about 9.6% a year at $11.63.
What did Monro's goodwill test find?
The filing says the second-quarter decline in market capitalization was "sustained throughout the quarter," so Monro ran a quantitative test. The estimated fair value of the company's single reporting unit came out above its carrying value, including goodwill, and no impairment was required. Monro added that if its growth and profitability plans fail, goodwill "could be subject to impairment."
In plain terms, the company's own valuation came out above book while the market priced the stock about 37% below book.
Is MNRO a good bet at $11.63?
It depends on whether anyone pays a price closer to the accounting value. The test does not set a price. It relies on management forecasts and valuation assumptions, and impairment tests often include a control premium a buyer might pay. The business itself is weak: second-quarter sales fell 1.8% to $283.6 million and Monro posted a net loss of $1.6 million, per the results release.
Who's making this call and why?
Kingdom Capital Advisors, posting as @kingdomcapadv, has been long Monro since early October. On November 2 it quoted the 10-Q passage and noted that book value is over $18. When another investor noted that the company's test and the market disagreed, it replied: "The straightforward read is 'we have credible bids on the table in excess of book we don't need to impair.'" It added that this was an auditor discussion, not a board one. That reading is Kingdom's; the filing mentions no bids.
Track record. In our tracking, Kingdom Capital is 4-14 (a .222 win rate) on 18 calls scored at 180 days against the S&P 500, with an average edge of -17.3 points. Its last 10 scored calls went 2-8. Its Monro calls are provisional and, through the November 3 close, trail the index by about 12 to 16 points. See the scoreboard.
Other supporters: Colin King (@valuedontlie), who disclosed a small position on October 29, wrote of the disclosure: "Don't see this often (ever?)." DOMO Capital (@DOMOCAPITAL) posted remarks it attributed to Monro's chief financial officer at a Gabelli conference on November 3, including that the Ares loan provides "flexibility for us to explore a wide range of the alternatives that we're currently evaluating." DOMO's summary: "They are selling the company soon." We have not reviewed a recording; Tom (@tomcvegas), who listened live, said it matched what he heard.
Who disagrees?
- Negative tangible book. Goodwill alone exceeds equity. If a buyer will not pay up for goodwill from past acquisitions, book value overstates what is left for shareholders.
- Buyers can wait. Mikro Kap David (@david_katunaric), who has no position, argued after the results that "potential buyers can afford to wait a lot longer than Monro can."
- A bull's own floor. Tom said on October 29 that Monro is "a $10-11 stock if no sale."
- No deadline. Management has given no timetable, and its new secured Ares loan runs to 2030.
- Weak trends. Full-year comparable sales are guided flat to slightly down, and net interest is expected at $28 million to $32 million a year.
What are the key facts to verify?
- The notes to the 10-Q for the goodwill test wording, and the balance sheet for equity and goodwill.
- Note 10 of the 10-Q for the rights plan terms and the November 6 expiry.
- The strategic review announcement and our earlier Icahn piece.
What would prove it right or wrong?
Right: Monro announces a sale of the company or of store groups at a price near book, or Icahn moves after the rights plan lapses on November 6.
Wrong: the review ends without a deal, comparable sales stay negative, or a later test leads to a goodwill write-down.
This is journalism and commentary, not investment advice. We hold no position unless stated.
